- Report
- May 2024
- 160 Pages
Global
From €4509EUR$4,949USD£3,915GBP
- Report
- March 2025
- 175 Pages
Global
From €4091EUR$4,490USD£3,552GBP
- Report
- March 2025
- 200 Pages
Global
From €4091EUR$4,490USD£3,552GBP
- Report
- April 2025
- 200 Pages
Global
From €4091EUR$4,490USD£3,552GBP
- Report
- May 2024
- 166 Pages
Global
From €4510EUR$4,950USD£3,916GBP
- Report
- October 2023
- 190 Pages
Global
From €4100EUR$4,500USD£3,560GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1822EUR$2,000USD£1,582GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1139EUR$1,250USD£989GBP
- Report
- April 2023
- 110 Pages
Global
From €4328EUR$4,750USD£3,758GBP
- Report
- May 2024
- 70 Pages
From €2688EUR$2,950USD£2,334GBP
- Report
- May 2024
- 67 Pages
South Africa
From €2050EUR$2,250USD£1,780GBP
- Book
- August 2021
- 672 Pages
- Book
- January 2021
- 160 Pages
- Book
- October 2020
- 752 Pages
- Book
- January 2020
- 112 Pages
- Book
- January 2019
- 496 Pages
- Book
- May 2018
- 872 Pages
- Book
- December 2017
- 1096 Pages

Psychosis is a mental health disorder characterized by a loss of contact with reality. Symptoms of psychosis can include delusions, hallucinations, disorganized thinking, and changes in behavior. It is often associated with schizophrenia, bipolar disorder, and other mental health conditions. Treatment for psychosis typically involves a combination of medication, psychotherapy, and lifestyle changes.
The psychosis market is a subset of the larger mental health market. It is composed of companies that provide products and services related to the diagnosis, treatment, and management of psychosis. These products and services include medications, psychotherapy, and lifestyle interventions. Additionally, companies in the psychosis market may provide support services such as patient education, advocacy, and community outreach.
Some companies in the psychosis market include Otsuka Pharmaceuticals, Sunovion Pharmaceuticals, and Lundbeck. Show Less Read more